
GLP-1 drugs can keep the brain cognitively sharp by reducing inflammation
TAK Image / Science photo library
Diabetes and weight loss treatments, such as the Ozempic and Wegoy, known as GLP-1 agonista, could significantly reduce the risk of any kind adulterAccording to a meta analysis of 26 clinical trials with more than 160,000 participants.
Semaglutide, treatments that contain medications like liraglutide and exenatide have been slightly linked Reduced dementia before the riskBut that would be seen based on observation studies health Records.
Now, Catriona Reddin From Galway to the University of Galway in Ireland and his colleagues have combined random tests, where 2 types of GLP-1 drugs were given diabetes It was not diagnosed with cognitive dementia or impairment, tested against a placebo. Taking these drugs seems to significantly reduce the risk of developing dementia or cognitive impairment at least six months of monitoring periods.
“The gold standard would be a great trial and a random judgment, but this is definitely another current proof (to past studies),” says Ziyad al-Aly At the University of Washington Medical School, Missouri, Missouri, did not participate in this research.
Can be diabetes Risk factor for dementiaSo controlling blood sugar levels has been suggested that this protection effect. For example, a study by Jingchuan guo The University of Florida and his colleagues call SGLT2 inhibitors, which lower blood sugar levels, helping to remove excessive glucose of the kidneys, based on the health records of Alzheimer’s disease or dementia.
But in Reddin and its control-controlled study, SGLT2 inhibitors were not linked to reduced risk of dementia, which suggests the protective effects of GLP-1 Drugs Go beyond blood sugar control.
The exact mechanism has been clear, these drugs have been associated with reduced inflammation Neuroinflammation It is increasingly recognized as a cause of dementia. By reducing chronic inflammation, it may Slow cell death in the brainReddin says.
They can also protect GLP-1 drugs Cardiovascular problemsFor example Building plate arteries and Hypertension arterialotherwise it could cause dementia.
“All the roads seem to be moving to Rome. We can see the observation from multiple studies and now is a study of controlled placebo studs, with the effect of these medications (anti-dementia),” says Al-Alyk.
Al-Aly stressed that we are still in a place where dementia is increasing the risk of developing, to dispose of the GLP-1 drug prescribed. But doctors can also tell you to provide these medications with 2 types of diabetes with a greater risk of cognitive decay. “This study will increase medical trend to prescribe these medications,” he noted.
Reddin warned that the analysis was quite short in the six-month follow-up period, and “large trials must be said to be a cognitive dementia and decline of glucose therapy.” Two clinical trials investigating Semaglutide It is expected to deduce this year as early as the initial therapy of Alzheimer’s.
Themes: